The drug, ACI193, was well tolerated in the first trial testing it in people, the company said. Results of the randomised, placebo-controlled study of 62 patients with early Alzheimer's disease were presented at the Alzheimer's Association's International Conference in Amsterdam.
from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/PiKMydY
0 Comments